Artificial heartmaker Carmat to start sales after EU approval
PARIS (Reuters) - Artificial heartmaker Carmat will begin sales of its devices from the second quarter of this year after a long-awaited European Commission approval, in a boost to its shares. Given recurring shortages of donors, Carmat's device aims to give patients with end-stage biventricular heart failure, a deadly condition where the heart is no longer able to pump blood adequately around the body, an alternative to hospital stays.
https://www.reuters.com/article/uk-carmat-outlook/french-artificial-heart-maker-carmat-sees-commercial-sales-in-q2-shares-surge-idUKKBN29B0MG?edition-redirect=uk